AI Terminal
SYNLAB AG
Legal Proceedings Report • Apr 30, 2024
723_rns_2024-04-30_fee79617-9886-4672-90d5-b8dd4048b472.html
Legal Proceedings Report
Open in ViewerOpens in native device viewer
News Details
Corporate | 30 April 2024 14:56
SYNLAB Italy has restored operations after cyber-attack
EQS-News: SYNLAB AG / Key word(s): Statement
SYNLAB Italy has restored operations after cyber-attack
30.04.2024 / 14:56 CET/CEST
The issuer is solely responsible for the content of this announcement.
SYNLAB Italy has restored operations after cyber-attack
- SYNLAB Italy has restored operations and will gradually resume all services for patients and customers.
- Due to a cyber-attack, SYNLAB had suspended operations in Italy as a precautionary measure.
- SYNLAB Group confirms no impact on operations in other countries.
SYNLAB AG (“SYNLAB”, FSE: SYAB) announces that SYNLAB Italy has started to gradually resume business operations. The majority of laboratories and blood collection points (BCPs) in Italy will again provide services to patients and customers as usual. Following a recent cyber-attack, the organization had immediately taken precautionary measures and suspended operations.
Furthermore, no operations outside Italy have been affected by the cyber-attack. SYNLAB Italy has established a task force with internal and external experts and continues to closely collaborate with law enforcement authorities to thoroughly investigate the incident.
SYNLAB remains committed to maintaining the highest standards of security and integrity. SYNLAB thanks its patients, partners, and customers for their patience and understanding during this incident.
– Ends-
For more information:
| Media contact: Diana Tabor, FTI Consulting |
+49 (0) 151 466 938 56 [email protected] |
| Investor contact: Etienne Ziller, SYNLAB |
+49 (0) 151 6701 3130 [email protected] |
About SYNLAB
- SYNLAB Group is the leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporates.
- Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
- SYNLAB operates in more than 30 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 27,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
- SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.64 billion in 2023.
- Ticker symbol: SYAB; ISIN: DE000A2TSL71
- More information can be found on www.synlab.com
SYNLAB – forward looking statements
This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction.
Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believes”, “expects”, “expected”, “may”, “will”, “would”, “should”, “seeks”, “pro forma”, “anticipates”, “intends”, “plans”, “estimates”, “estimated”, or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.
30.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | SYNLAB AG |
| Moosacher Straße 88 | |
| 80809 Munich | |
| Germany | |
| Phone: | +49 1701183753 |
| E-mail: | [email protected] |
| Internet: | www.synlab.com/ |
| ISIN: | DE000A2TSL71 |
| WKN: | A2TSL7 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1893187 |
| End of News | EQS News Service |